Dyne Therapeutics initiated with an Outperform at BMO Capital

BMO Capital analyst Kostas Biliouris initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $50 price target The firm says Dyne leverages TfR1-targeted delivery for neuromuscular disorder treatment, with clinical programs targeting Duchenne muscular dystrophy and myotonic dystrophy type 1. The DM1 market is large enough to accommodate multiple players, and Dyne could differentiate via a potential central nervous system benefit, the analyst tells investors in a research note. BMO sees potential 2026 commercialization in DMD.